151 related articles for article (PubMed ID: 16258442)
1. Finding the right dose.
Ratain MJ
Clin Adv Hematol Oncol; 2003 Sep; 1(9):517-8, 531. PubMed ID: 16258442
[No Abstract] [Full Text] [Related]
2. Finding the right dose for cancer therapeutics--can we do better?
Rubin EH; Anderson KM
Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182
[TBL] [Abstract][Full Text] [Related]
3. Dose selection in phase I studies: why we should always go for the most effective.
Haines IE
J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
[No Abstract] [Full Text] [Related]
4. Dose selection in phase I studies: why we should always go for the top.
Sleijfer S; Wiemer E
J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
[No Abstract] [Full Text] [Related]
5. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
6. Implications of dose intensity for cancer clinical trials.
Semin Oncol; 1987 Dec; 14(4 Suppl 4):1-44. PubMed ID: 3686043
[No Abstract] [Full Text] [Related]
7. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Ratain MJ; Eckhardt SG
J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
[No Abstract] [Full Text] [Related]
8. Review: new biological insights in early clinical studies.
Maur M; Sessa C
Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
[TBL] [Abstract][Full Text] [Related]
9. [Methodological aspects on new protocols in oncology].
Luporsi E
Bull Cancer; 2008 Oct; 95(10):979-83. PubMed ID: 19004729
[TBL] [Abstract][Full Text] [Related]
10. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
11. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
12. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
13. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
14. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
15. Use of healthy volunteers drives clinical oncology drug development decision making.
Iwamoto M; Iannone R; Wagner JA
Clin Pharmacol Ther; 2012 Nov; 92(5):571-4. PubMed ID: 23010649
[No Abstract] [Full Text] [Related]
16. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M
Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
[No Abstract] [Full Text] [Related]
17. Phase I's, photons, and philosophies: new tactics for exploratory clinical trials of concurrent chemoradiation.
Machtay M
J Clin Oncol; 2004 Jan; 22(2):214-6. PubMed ID: 14665615
[No Abstract] [Full Text] [Related]
18. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
19. Can a rational design for metronomic chemotherapy dosing be devised?
Maraveyas A; Lam T; Hetherington JW; Greenman J
Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
[No Abstract] [Full Text] [Related]
20. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
